Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-11-30 pm EST
7.910 USD   +5.33%
11/16Protagonist Therapeutics Reports Granting of Inducement Award
PR
11/10HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating
MT
11/08PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds
Sector news Other Biotechnology & Medical Research
11/30Insider Sell: Moderna
MT
11/30Insider Sell: Moderna
MT
11/30Transcript : Alnylam Pharmaceuticals, Inc. Presents at Piper Sandler 34th Ann..
CI
11/29Transcript : Alnylam Pharmaceuticals, Inc. Presents at 5th Annual Evercore IS..
CI
11/28ANI Pharmaceuticals Says US FDA Approved Its Generic Version of Prozac
MT
11/28Insider Sell: Moderna
MT
11/28Insider Sell: Moderna
MT
11/24Researchers test mRNA technology for universal flu vaccine
RE
11/23Insider Sell: Alnylam Pharmaceuticals
MT
11/22Mirati attracts fresh takeover interest - Bloomberg News
RE
11/22Generic drugmakers Teva and Sandoz make major push to biosimilars
RE
11/22CDC Says Pfizer-BioNTech, Moderna New Boosters Better Than Older Formulation in COVID-1..
MT
11/22Fauci pleads with Americans to get COVID shot in final White House briefing
RE
11/22Coeptis Therapeutics Holdings Inc. Engages IQVIA to Support Snap-Car Development Progra..
CI
11/22CORRECTED (OFFICIAL) -FOCUS-Generic drugmakers Teva and Sandoz make major push to biosi..
RE
11/21Truist Securities Initiates Coverage on Seagen at Hold With $135 Price Target
MT
11/21Morgan Stanley Lifts Price Target on Lonza Group, Maintains Overweight/In-Line Recommen..
MT
11/21Merck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugs
RE
11/21Insider Sell: Seagen
MT
11/21Insider Sell: Moderna
MT
11/18Insider Sell: Moderna
MT
11/18Insider Sell: Moderna
MT
11/18Pfizer's Updated Omicron Booster Shows Improved Immunity Against New Variants
MT
11/18Moderna Submits Application in Switzerland for Bivalent COVID-19 Vaccine
MT
11/18Pfizer/BioNTech Omicron shot shows immune response against BQ.1.1 in older adults
RE
11/18Big Pharma may have to reveal government deals in WHO's draft pandemic rules
RE
11/17Citigroup Downgrades IQVIA Holdings to Neutral From Buy, Adjusts Price Target to $245 F..
MT
11/16Transcript : Alnylam Pharmaceuticals, Inc. Presents at Stifel 2022 Healthcare..
CI
11/16Transcript : Alnylam Pharmaceuticals, Inc. Presents at 13th Annual Jefferies ..
CI
11/15Insider Sell: Seagen
MT
11/15Transcript : Moderna, Inc. Presents at 13th Annual Jefferies London Healthcar..
CI
11/15Immunogen's $6,220 ovarian cancer drug to be shipped within days
RE
11/14Japan's Daiichi Sankyo says mRNA COVID vaccine successful in booster trial
RE
11/14Stocks Drop as Markets Assess Fed Officials' Comments
MT
11/14Insider Sell: Moderna
MT
11/14Insider Sell: Moderna
MT
11/14Fed Officials' Interest-Rate Outlook Drives Stocks Lower
MT
11/14Sector Update: Health Care Stocks Hanging on for Monday Gains
MT
11/14Sector Update: Healthcare
MT
11/14Trending : Moderna Touts New Booster's Effectiveness Against Covid Variants
DJ
11/14US Stocks Mixed Midday; Fed Speakers Signal More to do in Fight Against Inflation
MT
11/14Moderna New Omicron Boosters Show Stronger Response, Indicate Neutralizing Activity Aga..
MT
11/14Midday Report: US Equity Indices Mixed as Treasury Yields Advance; Fed Spe..
MT
11/14US Equity Indices Mixed Midday As Treasury Yields Advance; Fed Speakers Signal More to ..
MT
11/14Moderna's Bivalent Booster Candidates Against COVID-19 Omicron Variants Meet Primary En..
MT
11/14Moderna's Omicron-targeting Booster Jabs Show Better Effect Over Prototype Vaccine
MT
11/14Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint o..
CI
11/11Insider Sell: Moderna
MT
11/11Moderna to Collaborate With Harbour BioMed in Developing Nucleic Acid-Based Immunothera..
MT
11/11TOP NEWS: Scottish Mortgage net asset value falls; cuts China exposure
AN
11/11HBM Unit, ModernaTX Sign License Deal to Develop Nucleic Acid-based Products; Shares Cl..
MT
11/10Harbour BioMed Enters into License and Collaboration Agreement with ModernaTX, Inc
CI
11/10Seagen Gets FDA Nod for Adcetris to Treat Blood Cancer in Children
MT
11/10IQVIA Holdings Collaborates with Clalit Health Services to Launch Prime Site in Israel
MT
11/10Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris« (Brentuximab Ve..
CI
11/10Mizuho Adjusts Price Target on IQVIA Holdings to $250 From $270, Maintains Buy Rating
MT
11/10IQVIA Announces Long-Term Collaboration with Clalit to Launch First Prime Site in Israe..
CI
11/10Seagen Appoints David Epstein as Chief Executive Officer
MT
11/10Transcript : Moderna, Inc. - Special Call
CI
11/10Seagen Inc. Announces Board Appointments
CI
11/10Seagen Inc. Announces CEO Changes
CI
11/10AstraZeneca lifts 2022 earnings outlook as cancer drugs boost results
RE
11/09Deutsche Bank Adjusts Moderna Price Target to $185 From $165, Maintains Buy Rating
MT
11/08Novavax cuts full-year revenue forecast
RE
11/08Transcript : IQVIA Holdings Inc. Presents at Credit Suisse 31st Annual Health..
CI
11/08Novavax says Omicron shot shows strong immune response as second booster
RE
11/07SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $145 From $142, Maint..
MT
11/07Chardan Lowers Price Target on Moderna to $186 From $188, Maintains Buy Rating
MT
11/07Insider Sell: Moderna
MT
11/06Moderna's Second Omicron-specific Bivalent COVID-19 Booster Wins Canadian Authorization
MT
11/04Moderna Says Health Canada Authorizes Second Omicron-Targeting Bivalent Booster
DJ
11/04Moderna, Inc. Receives Health Canada Authorization for Second Omicron-Targeting Bivalen..
CI
11/04Insider Sell: Moderna
MT
11/04Insider Sell: Moderna
MT
11/04Pfizer/BioNTech Omicron booster shows strong response after a month
RE
11/03Moderna Trims FY22 Outlook for COVID-19 Vaccine Sales Amid Production Delays
MT
11/03Tranche Update on Moderna, Inc.'s Equity Buyback Plan announced on August 3, 2022.
CI
11/03Tranche Update on Moderna, Inc.'s Equity Buyback Plan announced on February 24, 2022.
CI
11/03Moderna Third-Quarter Results Miss Views on Lower COVID-19 Vaccine Sales
MT
11/03Trending : Hampered by Supply Constraints, Moderna Cuts Sales Outlook
DJ
11/03Sector Update: Health Care Stocks Slip Pre-Bell Thursday
MT
11/03Moderna Q3 Earnings, Revenue Decline; Lowers 2022 COVID-19 Vaccine Sales Guidance; Shar..
MT
11/03Transcript : Moderna, Inc., Q3 2022 Earnings Call, Nov 03, 2022
CI
11/03Earnings Flash (MRNA) MODERNA Reports Q3 Revenue $3.36B, vs. Street Est of $3.53B
MT
11/03Moderna Q3 Earnings, Revenue Decline; Shares Down Pre-Bell
MT
11/03Moderna cuts annual sales forecast for COVID vaccine
RE
11/03Moderna, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/02HC Wainwright Cuts Price Target for Alnylam Pharmaceuticals to $415 From $430, Maintain..
MT
11/02JMP Securities Cuts Seagen's Price Target to $142 From $196, Keeps Market Outperform Ra..
MT
11/01Australia's CSL in mRNA vaccine licensing deal with U.S.-based Arcturus
RE
11/01Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
CI
11/01Pfizer boosts 2022 COVID vaccine forecast, looks to pivot with deals, new drugs
RE
11/01Moderna Says Japanese Regulator Approves Partial Change to New Drug Application for Omi..
MT
11/01Switzerland's Lonza Rolls Out New Capsule Delivery System
MT
11/01Moderna Wins Japanese Nod for COVID-19 Bivalent Booster Targeting Two Omicron Subvarian..
MT
11/01Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug A..
CI
11/01Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug A..
CI
10/31Insider Sell: Moderna
MT
10/28Morgan Stanley Adjusts Seagen's Price Target to $171 From $170, Keeps Overweight Rating
MT
10/28Morgan Stanley Adjusts Price Target on Alnylam Pharmaceuticals to $210 From $220, Reite..
MT
Upcoming event on PROTAGONIST THERAPEUTICS, INC.